Regulation
Rules, guidance and how the agencies work.
Stories
-
FDA releases guidance on new dietary ingredient notifications
The Food and Drug Administration announced the availability of final guidance titled "New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry." The guidance addresses frequently asked questions and provides recommendations for manufacturers and distributors on the identity and safety information that should be included in an NDIN.
-
FDA announces support for forward compatibility of eCTD 4.0
The FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research announced support for forward compatibility of Electronic Common Technical Document (eCTD) Version 4.0. This notice informs stakeholders that submissions based on eCTD 4.0 are supported for forward compatibility.
-
FDA authorizes emergency use of four animal drugs for New World screwworm
The FDA issued four Emergency Use Authorizations for products requested by Elanco US Inc., Zoetis Inc., Bimeda Animal Health Ltd., and Sergeant's Pet Care Products LLC to prevent infestations caused by New World screwworm larvae in various animals. The authorizations follow a HHS determination on August 18, 2025 that circumstances justify emergency use.
-
FDA launches Rare Disease Framework Initiative to gather public feedback
The FDA announced the Rare Disease Framework Initiative on October 14, 2026, aiming to create a fit-for-purpose framework for rare disease drug development. It will host an October 28 meeting at its White Oak campus to solicit feedback from patients, advocates, and industry.
-
Medtronic announces preliminary results of MiniMed exchange offer
Medtronic says its exchange offer to swap MiniMed shares for Medtronic ordinary shares was oversubscribed, with 298,024,452 Medtronic shares tendered. Medtronic intends to accept 55,032,401 shares for 252,813,348 MiniMed shares, estimating about 18.3% of tendered shares will be exchanged.
-
FDA actions, week of October 12, 2026: 2 approvals, 1 rule, 3 notices, 1 announcement
The FDA published 7 actions in the week of October 12 to 18, 2026: 2 approval announcements, 1 final rule in the Federal Register, 3 notices in the Federal Register and 1 press announcement.
-
FDA finalizes guidance on post-approval manufacturing changes to biosimilars
FDA announced the availability of a final guidance titled "Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers." The guidance supersedes the draft issued July 23 2024 and withdraws Q&A I.20 from the Q&A biosimilar development guidance.
-
FDA final rule permits salt substitutes in standardized foods
The rule, effective December 14, 2026, amends FDA's standards of identity to permit the use of salt substitutes in standardized foods. The change is intended to reduce sodium content in these foods.
-
FDA actions, week of September 28, 2026: 1 approval, 1 rule, 3 notices
The FDA published 5 actions in the week of September 28 to October 4, 2026: 1 approval announcement, 1 final rule in the Federal Register and 3 notices in the Federal Register.
-
FDA actions, week of October 5, 2026: 3 approvals, 5 rules, 7 notices, 1 announcement
The FDA published 16 actions in the week of October 5 to 11, 2026: 3 approval announcements, 5 final rules in the Federal Register, 7 notices in the Federal Register and 1 press announcement.
-
FDA corrects withdrawal notice of 16 ANDAs
The FDA issued a correction to a June 3, 2026 notice that announced the withdrawal of approval of 16 abbreviated new drug applications, effective July 6, 2026. The correction removes entries for ANDA 207366, ANDA 212957, and ANDA 218638, noting that Navinta LLC requested the approvals not be withdrawn, so those approvals remain in effect.
-
FDA withdraws approval of Amneal's celecoxib ANDA
FDA withdraws approval of abbreviated new drug application 208833 for celecoxib capsules 50 mg, 100 mg, 200 mg, and 400 mg held by Amneal Pharmaceuticals of New York, LLC. Amneal requested the withdrawal and waived its opportunity for a hearing.